Close Menu

NEW YORK – Cambridge, Massachusetts-based Pyxis Oncology on Tuesday said it has raised $152 million in a Series B funding round that it will use to advance its antibody-drug conjugate (ADC) pipeline.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.